Base business - renewed growth expected“While the base business was significantly impacted during 2023 due to various economic factors and organizational changes within one major customer, we expect renewed growth with our active ingredients..." today's news release
As noted in the Feb. news release the major client has begun to reorder after its reorganization:
"...we are pleased to announce that this customer has resumed ordering from Ceapro during Q1, 2024 with a +20metric ton order of avenanthramides." Feb. 2024 news release
There was no mention of the oat beta glucan dry powder evaluation by Symrise in the news release today, as mentioned in the Feb. 2024 news release, or the evaluation of the major client of the avenanthramide malted technology.